DE2246162B2 - Verfahren zur diagnose der hypercyanurie - Google Patents
Verfahren zur diagnose der hypercyanurieInfo
- Publication number
- DE2246162B2 DE2246162B2 DE19722246162 DE2246162A DE2246162B2 DE 2246162 B2 DE2246162 B2 DE 2246162B2 DE 19722246162 DE19722246162 DE 19722246162 DE 2246162 A DE2246162 A DE 2246162A DE 2246162 B2 DE2246162 B2 DE 2246162B2
- Authority
- DE
- Germany
- Prior art keywords
- hypercyanuria
- hydroxocobalamin
- hours
- injection
- urine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 title claims description 8
- LELOWRISYMNNSU-UHFFFAOYSA-N hydrogen cyanide Chemical compound N#C LELOWRISYMNNSU-UHFFFAOYSA-N 0.000 claims description 18
- 238000002347 injection Methods 0.000 claims description 17
- 239000007924 injection Substances 0.000 claims description 17
- RMRCNWBMXRMIRW-BYFNXCQMSA-M cyanocobalamin Chemical compound N#C[Co+]N([C@]1([H])[C@H](CC(N)=O)[C@]\2(CCC(=O)NC[C@H](C)OP(O)(=O)OC3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)C)C/2=C(C)\C([C@H](C/2(C)C)CCC(N)=O)=N\C\2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O RMRCNWBMXRMIRW-BYFNXCQMSA-M 0.000 claims description 10
- 210000002700 urine Anatomy 0.000 claims description 10
- 235000000639 cyanocobalamin Nutrition 0.000 claims description 5
- 239000011666 cyanocobalamin Substances 0.000 claims description 5
- 229960002104 cyanocobalamin Drugs 0.000 claims description 5
- 238000006303 photolysis reaction Methods 0.000 claims description 2
- 230000015843 photosynthesis, light reaction Effects 0.000 claims description 2
- 239000003708 ampul Substances 0.000 claims 1
- 238000002405 diagnostic procedure Methods 0.000 claims 1
- YOZNUFWCRFCGIH-BYFNXCQMSA-L hydroxocobalamin Chemical compound O[Co+]N([C@]1([H])[C@H](CC(N)=O)[C@]\2(CCC(=O)NC[C@H](C)OP(O)(=O)OC3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)C)C/2=C(C)\C([C@H](C/2(C)C)CCC(N)=O)=N\C\2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O YOZNUFWCRFCGIH-BYFNXCQMSA-L 0.000 description 36
- 235000004867 hydroxocobalamin Nutrition 0.000 description 18
- 239000011704 hydroxocobalamin Substances 0.000 description 18
- 229960001103 hydroxocobalamin Drugs 0.000 description 18
- XFXPMWWXUTWYJX-UHFFFAOYSA-N Cyanide Chemical compound N#[C-] XFXPMWWXUTWYJX-UHFFFAOYSA-N 0.000 description 4
- 238000003745 diagnosis Methods 0.000 description 4
- 208000034189 Sclerosis Diseases 0.000 description 3
- 150000002500 ions Chemical class 0.000 description 3
- 208000005374 Poisoning Diseases 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 208000029039 cyanide poisoning Diseases 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 230000029142 excretion Effects 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 125000004093 cyano group Chemical group *C#N 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 229940039227 diagnostic agent Drugs 0.000 description 1
- 239000000032 diagnostic agent Substances 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T436/00—Chemistry: analytical and immunological testing
- Y10T436/17—Nitrogen containing
- Y10T436/172307—Cyanide or isocyanide
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Urology & Nephrology (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Physiology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Food Science & Technology (AREA)
- Microbiology (AREA)
- Analytical Chemistry (AREA)
- Cell Biology (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR7133923A FR2153156B1 (OSRAM) | 1971-09-21 | 1971-09-21 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DE2246162A1 DE2246162A1 (de) | 1973-03-29 |
| DE2246162B2 true DE2246162B2 (de) | 1976-07-22 |
Family
ID=9083255
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE19722246162 Granted DE2246162B2 (de) | 1971-09-21 | 1972-09-20 | Verfahren zur diagnose der hypercyanurie |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US3903253A (OSRAM) |
| BE (1) | BE788780A (OSRAM) |
| DE (1) | DE2246162B2 (OSRAM) |
| FR (1) | FR2153156B1 (OSRAM) |
| GB (1) | GB1404324A (OSRAM) |
| LU (1) | LU66073A1 (OSRAM) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4279886A (en) * | 1979-01-02 | 1981-07-21 | University Patents, Inc. | Test for pancreatic exocrine function |
| BE1007839A6 (nl) * | 1993-12-20 | 1995-10-31 | Merkus Franciscus W H M Prof | Farmaceutische compositie voor de nasale toediening van hydroxocobalamine. |
| US5925625A (en) * | 1994-05-13 | 1999-07-20 | Merkus; Franciscus W. H. M. | Pharmaceutical composition for the intranasal administration of hydroxocobalamin |
| FR2740973B1 (fr) * | 1995-11-15 | 1998-02-06 | Lipha | Nouvelle forme d'administration de l'hydroxocobalamine et son utilisation dans les intoxications par les cyanures |
| US9585908B1 (en) | 2010-11-08 | 2017-03-07 | Chromaceutical Advanced Technologies, Inc. | Collyrium composition and method of using same |
| TWI818601B (zh) | 2021-10-29 | 2023-10-11 | 原創生醫股份有限公司 | 用於上呼吸道給藥之組成物及其用途 |
-
0
- BE BE788780D patent/BE788780A/xx not_active IP Right Cessation
-
1971
- 1971-09-21 FR FR7133923A patent/FR2153156B1/fr not_active Expired
-
1972
- 1972-09-13 LU LU66073A patent/LU66073A1/xx unknown
- 1972-09-14 GB GB4261872A patent/GB1404324A/en not_active Expired
- 1972-09-15 US US289291A patent/US3903253A/en not_active Expired - Lifetime
- 1972-09-20 DE DE19722246162 patent/DE2246162B2/de active Granted
Also Published As
| Publication number | Publication date |
|---|---|
| US3903253A (en) | 1975-09-02 |
| FR2153156A1 (OSRAM) | 1973-05-04 |
| FR2153156B1 (OSRAM) | 1975-10-10 |
| GB1404324A (en) | 1975-08-28 |
| LU66073A1 (OSRAM) | 1973-01-17 |
| DE2246162A1 (de) | 1973-03-29 |
| BE788780A (fr) | 1973-01-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Pazzagli et al. | Amnesic properties of scopolamine and brain acetylcholine in the rat | |
| DE69731386T2 (de) | Verfahren zur behandlung von asthma mit o-desulfatisiertem heparin | |
| EP0065747B1 (de) | Nonapeptid zur Behandlung von Suchtmittelentzugserscheinungen | |
| DE69132797T2 (de) | Verwendung von Vincristin zur Auswertung von Wirkstoffen in Zentralnervensystems | |
| DE2246162B2 (de) | Verfahren zur diagnose der hypercyanurie | |
| DE3317692A1 (de) | Verwendung von metkephamid oder eines pharmazeutisch unbedenklichen salzes hiervon als analgetikum bei traechtigen weiblichen tieren und insbesondere bei schwangeren frauen | |
| EP0541192A1 (de) | Verwendung von Opiat-Antagonisten zur Behandlung von endogener Hyperinsulinämie | |
| DE60220512T2 (de) | Verwendung von flumazenil zur herstellung eines medikaments für die behandlung von kokainabhängigkeit | |
| Isojarvi et al. | Effects of carbamazepine on pituitary responsiveness to luteinizing hormone‐releasing hormone, thyrotropin‐releasing hormone, and metoclopramide in epileptic patients | |
| DE69636393T2 (de) | Montirelin zur verhinderung der schlafapnoe | |
| DE69308762T2 (de) | Behandlung des Muskulschwunds | |
| EP0132595B1 (de) | Tokolytisches Mittel | |
| DE2163054A1 (de) | Lokalanaesthetisches mittel | |
| EP0013962A1 (de) | Aminosäuren und Mineralsalze enthaltende Infusionslösung | |
| DE4026600A1 (de) | Mittel zur tsh-suppression und behandlung von struma | |
| Cutler et al. | Effects of δ-aminolaevulinic acid on contractile activity of rabbit duodenum | |
| Olson Jr | Naloxone accelerates the rate of ventilatory acclimatization to hypoxia in awake rats | |
| EP1244442B1 (de) | Verfahren zur auffindung von nukleotidsyntheseinhibitoren mit weniger nebenwirkungen | |
| DE69701139T2 (de) | Verwendung von lofexidin zur herstellung eines arzneimittels zur behandkung der mit konzentrationsschwäche einhergehenden hyperaktivität | |
| AT214700B (de) | Verfahren zur Vermeidung von paresis puerperalis bei Rindvieh | |
| DE2750920C3 (de) | Verwendung von Fibrinopeptiden A und B | |
| DE2345291A1 (de) | Therapeutisches mittel | |
| DE1467743A1 (de) | Verfahren zur Herstellung eines Praeparats mit verlaengerter Vitamin B 12-Wirkung | |
| Goerz | Klinik und Therapie der Porphyria cutanea tarda | |
| DE1920730C (de) | Analgetikum |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C3 | Grant after two publication steps (3rd publication) | ||
| E77 | Valid patent as to the heymanns-index 1977 |